Syncom Formulations Reports Quarterly Results with Strong Performance Across Segments
Syncom Formulations (India) Limited has released its un-audited financial results for the quarter ended June 30, 2026. The results encompass both standalone and consolidated figures, demonstrating performance across the company's three operating segments.The Consolidated Financial Statement showed a total income of 13,335.58 lakhs, up from 12,293.64 lakhs in the same quarter of the previous year. Profit before tax for the period was recorded at 3,225.22 lakhs. The company's Total Comprehensive Income stood at 2,866.55 lakhs.
The financial results were approved by the Board of Directors. A Limited Review Report on the Consolidated Unaudited Financial Results for the Quarter and Three Months ended June 30, 2026 was also completed by statutory auditors.
Consolidated Financial Highlights (Quarter Ended 30/06/2026)
The key financial figures for the consolidated results are presented below:| Particulars | Consolidated Results (Unaudited) | Previous Year's Consolidation (Audited) |
|---|---|---|
| Revenue from Operations | 12,552.64 Lakhs | 11,690.17 Lakhs |
| Other Income | 782.94 Lakhs | 603.47 Lakhs |
| Total Income | 13,335.58 Lakhs | 12,293.64 Lakhs |
| Profit Before Tax (PBT) | 3,225.22 Lakhs | 10,108.26 Lakhs |
| Total Comprehensive Income | 2,866.55 Lakhs | 7,283.07 Lakhs |
| Basic EPS (Continuing Operations) | 0.26 | 0.81 |
Segment Performance
The company operates in three segments: Pharmaceuticals Drugs & Formulations, Trading of Commodities, and Renting of Property. The segment-wise results show the breakdown of revenue and profitability across these areas for the quarter ended June 30, 2026.| Segment Particulars | Revenue (Lakhs) | Profit Before Tax & Interest (Lakhs) |
|---|---|---|
| Pharmaceuticals Drugs & Formulations | 12,552.64 | 3,225.22 |
| Trading of Commodities | 1,824.49 | 1,010.82 |
| Renting of Property | 1,318.85 | 77.41 |
| Total Segment Revenue | 13,335.58 | N/A |
Accounting and Operational Notes
The company also provided standalone un-audited results for the quarter ended June 30, 2026, with a revenue from operations of 12,465.95 lakhs. The Qtrly Standalone Profit before tax was reported at 3,190.88 lakhs.A significant operational change noted is that the company has methodically updated its approach to calculating Earnings Per Share (EPS). Previously, EPS was calculated based on Total Comprehensive Income. To comply with Indian Accounting Standard 33, the EPS methodology has been changed to calculate using Profit After Tax attributable to equity shareholders, leading to a restatement of comparative EPS figures in preceding periods.
The Limited Review Report concluded that nothing came to the auditor's attention regarding the accompanying Statement that suggests it contains any material misstatement or fails to disclose required information under applicable accounting standards and recognized accounting practices.
SYNCOMF Stock Price Movement
On Tuesday, shares of Syncom Formulations (India) Limited rallied to settle at ₹14.53, posting a 1.81% gain in the market close. The stock traded within a tight range for the day, holding above its low and closing with high volume compared to the previous session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: